Statement on President Biden’s Grant of Clemency for Leonard Peltier From Kevin Sharp, Co-Vice Chairman Sanford Heisler Sharp McKnightNASHVILLE, Tenn., Jan. 20, 2025 (GLOBE NEWSWIRE) -- This morning, President Biden granted clemency to political activist and Native American community advocate, Leonard Peltier, who has been wrongfully imprisoned for 49 years. The plight of Leonard Peltier has been in the spotlight for decades with prominent personalities including Nelson Mandela, Bishop Desmond Tutu, Pope Francis, among hundreds of others, calling for his release.
Transaction in Own SharesTransaction in Own Shares
AN OPEN LETTER TO PRESIDENT DONALD J. TRUMPWashington, D.C., Jan. 20, 2025 (GLOBE NEWSWIRE) -- January 20, 2025
Beaverton Foods Welcomes Juan Gluth as Head of SalesBEAVERTON, Ore., Jan. 20, 2025 (GLOBE NEWSWIRE) -- Beaverton Foods, a leader in premium condiments for nearly a century, is excited to announce the appointment of Juan Gluth as Head of Sales. With more than 20 years of leadership experience in the food and beverage industry, Gluth brings a wealth of expertise in driving revenue growth, brand development, and market expansion.
WISeKey Launches the Presale of SEALCOIN at Davos 2025 – The First Post-Quantum Crypto Token Revolutionizing TIoT TransactionsWISeKey Launches the Presale of SEALCOIN at Davos 2025 – The First Post-Quantum Crypto Token Revolutionizing TIoT Transactions
Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya VaccineSaint-Herblain (France), January 20, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ®, which showed a sustained 98.3% sero-response rate one-year after single vaccination. These results support and strengthen the pivotal data previously reported for adolescents (12 to 17 years old) which supported filing for potential label extension to this age group in the U.S.1, Europe, and Canada2. Data from this trial are also expected to support licensure of IXCHIQ® in Brazil, which would be the first potential approval for use in endemic populations.
LambdaTest Launches SmartUI Figma-Web CLI: A Major Enhancement to Figma CLINew SmartUI Figma-Web CLI bridges the gap between Figma designs and live web interfaces, empowering teams to ensure visual consistency across platforms.
CNL’S CNRI-H Program Continues Strong Growth Thanks to New Projects With Repare Therapeutics and Defence TherapeuticsCanada’s national nuclear laboratories announces new projects with leading Canadian biopharmaceutical companies through collaborative research program
Group FH ORTHO announced the Launch of JARVIS the New Round Baseplate for Reverse Prosthesis in the USA!HEIMSBRUNN, France, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Group FH ORTHO, a global leader in orthopedic prosthetic technologies, is proud to announce the launch of JARVIS, its new round baseplate for reverse shoulder prostheses in the USA.
Vanguard Starts 2025 Strong with ARA, World of Concrete AppearancesVanguard to showcase cutting-edge commercial power solutions for compact equipment and rental industries
BPR Hub Raises $2.6M to Make World-Class Compliance Accessible to All ManufacturersAI-powered platform BPR Hub cuts certification time by 40% as manufacturers struggle with mounting regulatory requirements.
PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS IsraelTORONTO, Jan. 20, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has executed an agreement with Merhavim Mental Health Centre of Beer Yaakov, Israel (“Merhavim”). All data generated in the clinical trial, entitled “MDMA Assisted Psychotherapy for PTSD of Early Sexual Trauma Compared to All Trauma in Adulthood”, will be licensed to PharmAla for regulatory and commercial purposes in exchange for the clinical trial material, which will be provided by PharmAla on a zero-cost basis. MAPS Israel, an Israeli non-profit organization whose mission is to develop psychedelic research and educational programs based in public health, is also a partner to the clinical trial.
Rivalry’s Addition of $TRUMP Kickstarts Always-On Meme Coin Crypto Payment StrategyRivalry to Pursue Responsive Crypto Payment Strategy, Adding Additional Meme Coins As Dictated By Market Interest to Support Acquisition, Revenue, and Marketing Opportunities
Dave Marshall to Retire as Chief Financial Officer of Premier Truck Rental; Welcomes Taylor Mann as SuccessorFort Wayne, IN, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Premier Truck Rental (PTR) announces the upcoming retirement of Dave Marshall, Chief Financial Officer, who will be stepping down after 4 and a half years of impactful service.
Gentex to Bring Premier Custom Car Builder Ringbrothers to Grand Rapids for the Michigan International Auto ShowZEELAND, Mich., Jan. 20, 2025 (GLOBE NEWSWIRE) -- Gentex Corporation (
NASDAQGNTX) is once again the presenting sponsor of Michigan International Auto Show, and to celebrate, the company is partnering with Ringbrothers, a world-renowned custom car builder, to bring their recently unveiled 1970 Plymouth ‘Cuda, INFECTED,” to the show.
Complete Solar to Report Fourth Quarter and Full Year 2024 Results on January 21, 2025OREM, Utah, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Complete Solar Holdings, Inc. d/b/a Complete Solar (“Complete Solar” or the “Company”) (Nasdaq: CSLR), a solar technology, services, and installation company, today announced it will release its fourth quarter and full year 2024 results, before market open on Tuesday, January 21, 2025. T.J. Rodgers and members of the management team will host a webcast conference call on January 21, at 2:00 PM ET.
Terra Balcanica Drills 436 g/t AgEq Over 19.6 m At Antimony-Silver Discovery in Bosnia News Release Video: Terra Balcanica produced a technical webinar to explain the drill results
FERRARI N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAMMaranello (Italy), January 20, 2025 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company”) informs that the Company has purchased, under the Euro 150 million share buyback program announced on December 5, 2024, as the sixth tranche of the multi-year share buyback program of approximately Euro 2 billion expected to be executed by 2026 in line with the disclosure made during the 2022 Capital Markets Day (the “Sixth Tranche”), the additional common shares - reported in aggregate form, on a daily basis - on the Euronext Milan (EXM) as follows:
PyroGenesis Receives $1.85 Million Payment Under Existing Drosrite™ Contract with Saudi ClientMONTREAL, Jan. 20, 2025 (GLOBE NEWSWIRE) -- PyroGenesis Inc. (“PyroGenesis”) (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY), a high-tech company that designs, develops, manufactures and commercializes advanced plasma processes and sustainable solutions which are geared to reduce greenhouse gases (GHG) and address environmental pollutants, announces the receipt of a US$1.28 million (CA$1.85 million) payment representing a portion of an outstanding receivable under PyroGenesis’ existing CA$25+ million Drosrite™ contract with Radian Oil and Gas Services Company.
Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in EuropeSHANGHAI, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, and its wholly-owned subsidiary, TopAlliance Biosciences Inc. (TopAlliance Biosciences), announced a distribution and marketing partnership with LEO Pharma for toripalimab in Europe. This collaboration aims to promote the accessibility of toripalimab in Europe, offering high-quality, innovative treatments to patients across up to 32 European countries.
Brunswick Corporation Earns Spot on Forbes' Inaugural List of America's Most Trusted CompaniesMETTAWA, Ill., Jan. 20, 2025 (GLOBE NEWSWIRE) -- Brunswick Corporation (
NYSEBC), the world’s largest marine technology company, has been named to Forbes' inaugural 2025 list of America’s Most Trusted Companies. Among the thousands of companies that were researched for this honor, only 300 made the final list. Brunswick ranked eighth within the Engineering and Manufacturing category.
Orderly Deploys on Sonic’s EVM to Deliver Omnichain LiquiditySINGAPORE, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Web3 liquidity layer Orderly has announced that it has deployed its chain-agnostic infrastructure on EVM Layer 1 Sonic. Orderly’s integration will bring its omnichain orderbook to Sonic, enabling developers and users of the new L1 to access deep liquidity.
Rivalry Adds $TRUMP Meme Coin as Crypto Payment MethodGlobal Crypto Casino Rivalry Becomes First Betting Operator to Accept U.S. President-Elect Donald Trump’s Official Solana Meme Coin $TRUMP for Deposit
MBZUAI welcomes the world to Abu Dhabi for a leading NLP conferenceABU DHABI, United Arab Emirates, Jan. 18, 2025 (GLOBE NEWSWIRE) -- The 31st International Conference on Computational Linguistics (COLING 2025) launches in Abu Dhabi tomorrow (19 January), with local organizers Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) welcoming more than 1,500 global attendees.
Blockchain Ball: Honoring the Inauguration of the 47th President and Celebrating Blockchain’s Role in the Global Economy At The Kennedy Center, Washington DCWASHINGTON, Jan. 18, 2025 (GLOBE NEWSWIRE) -- In a historic celebration of leadership and technological innovation, Brock Pierce, DNA Holdings, and Ambassador Paolo Zampolli are proud to host the Blockchain Ball, an exclusive event honoring the inauguration of the 47th President of the United States, Donald J. Trump. This distinguished gathering will highlight blockchain’s transformative impact on the global economy while celebrating a new era of leadership.
TELUS ALERT: Bragar Eagel & Squire, P.C. is Investigating TELUS International (Cda) Inc. on Behalf of TELUS Stockholders and Encourages Investors to Contact the FirmNEW YORK, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against TELUS International (Cda) Inc. (“TELUS” or the “Company”) (
NYSETIXT) on behalf of TELUS stockholders. Our investigation concerns whether TELUS has violated the federal securities laws and/or engaged in other unlawful business practices.
SIMPPLE Ltd. Receives Nasdaq Notifications Regarding Minimum Stockholders’ Equity Deficiency and Annual Meeting DeficiencySingapore, Jan. 17, 2025 (GLOBE NEWSWIRE) -- SIMPPLE Ltd. (
NASDAQSPPL) (“SIMPPLE” or “the Company”), an advanced technology solution provider in the emerging property-technology (“PropTech”) space, today announced that it has received letters from the Listing Qualification staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that the Company does not meet the minimum stockholders’ equity requirement and annual meeting requirement.
INVESTIGATION ALERT (NASDAQ: WBA): DiCello Levitt LLP Is Investigating Investor Claims Against Walgreens Boots Alliance, Inc. and Encourages WBA Investors with Losses to Contact the FirmSAN DIEGO, Jan. 17, 2025 (GLOBE NEWSWIRE) -- DiCello Levitt LLP announces that it is investigating whether Walgreens Boots Alliance, Inc. (“Walgreens” or the “Company”) (
NASDAQWBA) violated the federal securities laws, issued false and/or misleading statements, and/or failed to disclose information required to be disclosed to investors.
Uniti Group Inc. Announces Pricing of $589 Million Fiber Securitization Notes OfferingLITTLE ROCK, Ark., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Uniti Group Inc. (the “Company,” “Uniti,” or “we”) (Nasdaq: UNIT) today announced that Uniti Fiber ABS Issuer LLC and Uniti Fiber TRS Issuer LLC, limited-purpose, bankruptcy remote subsidiaries of Uniti (collectively, the “Issuers”), have priced their offering of $589,000,000 aggregate principal amount of secured fiber network revenue term notes, consisting of $426,000,000 5.9% Series 2025-1, Class A-2 term notes, $65,000,000 6.4% Series 2025-1, Class B term notes and $98,000,000 9.0% Series 2025-1, Class C term notes, each with an anticipated repayment date in April 2030 (collectively, the “Notes”). Collectively, the Notes have a weighted average yield of approximately 6.5%. The Notes will be secured by certain fiber network assets and related customer contracts in the State of Florida and the Gulf Coast region of Louisiana, Mississippi and Alabama. Each of the Issuers and its direct parent entities and subsidiaries have been designated as “unrestricted subsidiaries” under Uniti’s credit agreement and the indentures governing its outstanding senior notes. The offering is expected to close on February 3, 2025.
President Biden Grants Clemency to Over 2,500 Drug War Victims in Final DaysLPP Applauds the President’s Actions Addressing Disparate Harms From the War on Drugs After Years of Advocacy.
BioAge Labs, Inc. Class Action Notice: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the BIOA Class ActionSAN DIEGO, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all shareholders who purchased stock pursuant and/or traceable to the BioAge Labs, Inc. (
NASDAQBIOA) registration statement for the initial public offering (IPO) held on September 26, 2024. BioAge claims it is a "clinical stage biopharmaceutical company” that develops therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging.
Robbins LLP Urges MU Stockholders with Large Losses to Contact the Firm for Information About the Micron Technology, Inc. Class ActionSAN DIEGO, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Micron Technology, Inc. (
NASDAQMU) securities between September 28, 2023 and December 18, 2024. Micron designs, develops, manufactures, and sells memory and storage products, including, inter alia, dynamic random access memory (“DRAM”), NAND, NOR, and high-bandwidth memory (“HBM”) semiconductor devices.
Lifecore Biomedical Announces Special Stockholder MeetingCompany Seeking to Remove Convertible Preferred Stock Exchange Cap to Permit Potential Conversion of Series A Preferred Stock as Contemplated by the Series A Preferred Stock Terms
Robbins LLP Urges REGN Stockholders with Large Losses to Contact the Firm for Information About the Class Action Against Regeneron Pharmaceuticals, IncSAN DIEGO, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (
NASDAQREGN) securities between November 2, 2023 and October 30, 2024. Regeneron is a biotechnology company that designs products for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, among others.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)SAN CARLOS, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (
NASDAQIOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on January 16, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 224,550 shares of Iovance’s common stock to forty-one new, non-executive employees.
MBDA’s Eric Morrissette Launches MBDA’s Innovation Lab to Empower Minority Business EnterprisesWASHINGTON, DC, Jan. 17, 2025 (GLOBE NEWSWIRE) -- In his final act, the outgoing Head of MBDA, Eric Morrissette, unveiled the Minority Business Development Agency’s (MBDA) Innovation Lab, a transformative series of initiatives designed to harness technology and innovation in support of minority business enterprises (MBEs).
SBA Administrator Guzman Outlines New MySBA Digital Experience Transforming How Business Owners Interact with SBANew MySBA Experience Builds on SBA’s Efforts to Transform Customers’ Experiences with the Agency via Innovative Digital Tools
Fortis Inc. to Hold Teleconference and Webcast on February 14 to Discuss 2024 Annual ResultsST. JOHN'S, Newfoundland and Labrador, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Fortis Inc. ("Fortis" or the "Corporation") (TSX/NYSE: FTS) will release its 2024 financial results on Friday, February 14, 2025. A teleconference and webcast will be held the same day at 8:30 a.m. (Eastern). David Hutchens, President and Chief Executive Officer and Jocelyn Perry, Executive Vice President and Chief Financial Officer will discuss the Corporation's 2024 annual financial results.
Jianzhi Education Technology Group Company Limited Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyBEIJING, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Jianzhi Education Technology Group Company Limited (the “Company” or “Jianzhi”) (
NASDAQJZ), a leading provider of digital educational content in China, today announced that the Company has received written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) dated January 15, 2025, indicating that for the last 30 consecutive business days, the closing bid price for the Company’s American depositary shares (the “ADSs”) was below the minimum bid price of US$1.00 per share requirement set forth in Nasdaq Listing Rules. The Nasdaq notification letter has no current effect on the listing or trading of the Company’s ADSs on The Nasdaq Capital Market.
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)WALTHAM, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective January 1, 2025, the company granted a non-qualified stock option to purchase 60,000 shares of its common stock to one new employee under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.
